The birth of baby Hugo Powell in the United Kingdom last December has been widely celebrated as a triumph of reproductive medicine. For the estimated one in every 5,000 women worldwide born with a condition that leaves them without a viable womb, including thousands of women across Africa, the question is now a harder one: when will this breakthrough reach them?
Grace Bell, a woman in her 30s from Kent in southern England, gave birth to Hugo just before Christmas 2025 after receiving a womb transplant from a deceased donor. She is the second woman in the UK to give birth following a womb transplant, and the first following a transplant from a deceased donor. The research team believes Hugo is the third baby born in Europe after a deceased donor womb transplant.
Bell was born with Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome, a congenital condition in which the uterus is absent or underdeveloped. Women with MRKH syndrome do not have periods because the womb is absent or underdeveloped, but they usually have functioning ovaries. The condition affects approximately one in every 5,000 women globally, meaning tens of thousands of women across Africa are living with the syndrome, many of whom have never received a clinical diagnosis and do not know why they cannot conceive.
The womb transplant that made Hugo’s birth possible was funded entirely by the charity Womb Transplant UK and forms part of a clinical research trial of 10 planned procedures. Globally, over 100 womb transplant operations have been performed and more than 70 healthy babies have been born as a result. The overwhelming majority of those procedures have taken place in Sweden, the United States, Brazil, Germany, and the United Kingdom, countries with the surgical expertise, fertility infrastructure, and post-operative support systems the procedure demands.
Africa currently has no approved womb transplant programme. The procedure requires a transplant-capable hospital, a fertility clinic, in vitro fertilisation (IVF) capacity, immunosuppressant management over an extended period, and either a living donor or a specific deceased donor consent arrangement that sits outside normal organ donation frameworks. Most African health systems, including Ghana’s, do not yet have all of those elements working in concert.
In Ghana, the conversation about reproductive medicine has largely centred on IVF access, maternal mortality, and the rollout of the new Free Primary Healthcare policy, which is expected to begin in March 2026 with a focus on preventive care and early detection of non-communicable diseases. The Ghana Medical Trust Fund, popularly known as MahamaCares, has been allocated GH¢2.3 billion in the 2026 budget to support patients with conditions including hypertension, diabetes, and cancer. MRKH is not currently part of any structured government reproductive health programme.
Consultant gynaecologist Professor Richard Smith, from Imperial College Healthcare National Health Service (NHS) Trust, who has researched womb transplantation for more than 25 years, said the birth shows that girls and young women told they do not have a womb could now have hope of carrying their own child. That message, delivered in London, takes on a different weight in Accra, Kumasi, Nairobi, or Lagos, where access to even basic fertility counselling for women with MRKH remains rare.
The UK trial is currently seeking to determine whether womb transplantation can become an approved and routine treatment, rather than an experimental one. If it achieves that status, the next challenge for global health advocates will be ensuring that the technology does not follow the same trajectory as IVF, which took decades to become accessible in low and middle income countries and remains financially out of reach for most Ghanaian families today.
Hugo Powell’s birth is, by any measure, a medical miracle. The challenge ahead is ensuring that the science it represents does not remain the exclusive property of the world’s wealthiest health systems.
